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Skeletal muscle wasting is commonly associated with chronic kidney disease (CKD), resulting in increased morbidity and
mortality. However, the link between kidney and muscle function remains poorly understood. Here, we took a
complementary interorgan approach to investigate skeletal muscle wasting in CKD. We identified increased production
and elevated blood levels of soluble pro-cachectic factors, including activin A, directly linking experimental and human
CKD to skeletal muscle wasting programs. Single-cell sequencing data identified the expression of activin A in specific
kidney cell populations of fibroblasts and cells of the juxtaglomerular apparatus. We propose that persistent and increased
kidney production of pro-cachectic factors, combined with a lack of kidney clearance, facilitates a vicious kidney/muscle
signaling cycle, leading to exacerbated blood accumulation and, thereby, skeletal muscle wasting. Systemic
pharmacological blockade of activin A using soluble activin receptor type IIB ligand trap as well as muscle-specific adeno-
associated virus–mediated downregulation of its receptor ACVR2A/B prevented muscle wasting in different mouse
models of experimental CKD, suggesting that activin A is a key factor in CKD-induced cachexia. In summary, we
uncovered a crosstalk between kidney and muscle and propose modulation of activin signaling as a potential therapeutic
strategy for skeletal muscle wasting in CKD.
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Introduction
Chronic kidney disease (CKD) affects approximately 10%–15% 
of the world’s population (1) and represents a state of progres-
sive and irreversible loss of kidney function (2). Interestingly, 
two-thirds of adults living with CKD show signs of cachexia (3), 
a wasting syndrome characterized by progressive depletion of 
skeletal muscle mass that significantly increases morbidity and 
mortality and compromises patients’ quality of life because of 
loss of autonomy and fatigue (4, 5). Given that interventions for 
CKD-related cachexia are limited to nutritional support, correc-
tion of acidosis, physical exercise (6), and experimental pharma-
cological therapies (e.g., recombinant human growth hormone) 
(7), a better understanding of the pathophysiological processes 
that govern this condition may facilitate the discovery of innova-
tive and effective therapies.
The kidney plays a pivotal role in the maintenance of body 
homeostasis, not only by regulating blood pressure and fluid bal-
ance and clearing waste products, but also by acting as a major 
endocrine organ (8). For example, it is well known that the devel-
opment of tubulointerstitial fibrosis compromises renal erythropoi-
etin production, resulting in anemia (9). Also, kidney injury may 
lead to the release of circulating signals that directly affect multiple 
structures, including central and peripheral vasculature, myocardi-
um, skeleton, and lungs (10–12). Importantly, a direct association 
between kidney damage and muscle wasting is yet to be established.
Cachexia-induced muscle loss is generally explained by 
reduced protein synthesis, increased degradation, or a relative 
imbalance of the two (13). Different hormones and cytokines 
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in Kif3aΔTub mice (Supplemental Figure 1, B and C) without fea-
tures of myofiber degeneration (e.g., centrally nucleated fibers) 
(Supplemental Figure 1D).
Quantification of cross-sectional area of TA muscle showed a 
leftward shift at the terminal time point in Kif3aΔTub muscle com-
pared with WT (Figure 1G), resulting in a large decrease in the 
average fiber size (1074 μm2 in WT compared with 661 μm2 in 
Kif3aΔTub). Myofiber size decreased in every myosin heavy chain 
(MHC) isoform subtype among all muscles (Supplemental Figure 
1, E and H). Specific forces generated by EDL muscles were also 
reduced in Kif3aΔTub compared with WT mice (Figure 1H). Togeth-
er, these data show that skeletal muscle of Kif3aΔTub mice with 
CKD undergoes both functional and structural changes consistent 
with muscle wasting.
Altered protein synthesis, proteasome, and autophagic flux in 
CKD-related muscle wasting. Muscle growth depends on the fusion 
of muscle stem cells to form myofibers and on protein synthe-
sis that drives fiber hypertrophy (17). Given our observation of 
decreased muscle fiber number, we quantified the number of 
muscle stem cells in EDL muscles and found a 60% reduction in 
Kif3aΔTub (Figure 2A). In vitro, Kif3aΔTub stem cells were able to fol-
low their normal program of differentiation and showed a similar 
proportion of myogenic positive cells as those from WT mice (Fig-
ure 2B). Furthermore, we identified a strong reduction in mRNA 
levels of insulin-like growth factor 1 (Igf1), a key regulator of cellu-
lar proliferation, in muscles from Kif3aΔTub compared with WT mice 
(data not shown).
Skeletal muscle wasting can also be explained by an imbal-
ance between protein synthesis and degradation. The capacity for 
muscle protein synthesis was assessed in vivo using a puromycin 
incorporation analysis (Surface Sensing of Translation, SUnSET; 
ref. 25), which revealed a strong impairment of protein production 
in muscles from Kif3aΔTub mice (Figure 2C). Then, we investigated 
the status of the ubiquitin-proteasome and autophagy-lysosome 
systems. Atrophy-related ubiquitin ligases Atrogin-1, Musa, Murf1, 
Itch, and Fbxo31 were all upregulated in muscles from Kif3aΔTub 
mice (Supplemental Figure 2A). Furthermore, the expression of 
several genes associated with autophagy, including Bnip3, Becn1, 
and Ambra1, was also significantly upregulated in muscles from 
Kif3aΔTub mice (Supplemental Figure 2B).
Colchicine, by destabilizing the microtubule network, blocks 
the delivery of autophagosomes to lysosomes, resulting in the 
accumulation of autophagic vacuoles, and therefore, is an excel-
lent tool for monitoring autophagy flux in vivo (26). Colchicine 
treatment led to a stronger accumulation of lipidated LC3 and p62 
in muscles from Kif3aΔTub mice, suggesting autophagy activation 
(Figure 2D). Together, these findings show a shift in the balance 
from muscle synthesis to muscle degradation.
Altered mitochondrial structure and function in CKD-related 
muscle wasting. Next, we examined the metabolic status of muscle 
fibers by profiling the proportion of fibers displaying high levels 
of succinate dehydrogenase (SDH) activity. EDL and soleus mus-
cles from Kif3aΔTub mice contained a lower proportion of oxidative 
fibers (Figure 2E and Supplemental Figure 2C) and a lower expres-
sion of genes encoding respiratory chain complex (RCC) pro-
teins (Supplemental Figure 2D) compared with WT mice. While 
mitochondria density in both subsarcolemmal (SS) and intramy-
induce muscle wasting through the activation or inhibition of inter-
secting intracellular signaling pathways (14). In particular, proin-
flammatory cytokines (e.g., IL-6, IL-1β, and TNF-α) trigger mus-
cle wasting by activating pathways such as NF-κB and JAK/STAT 
(15, 16). Furthermore, a major cause of muscle loss is driven by 
an impairment in insulin-like growth factor 1/insulin/PI3K/AKT 
signaling (17). Activin A is also a key negative regulator of muscle 
growth that inhibits muscle growth and promotes its degradation 
(18, 19). Together, these signaling networks have been described 
in association with multiple chronic diseases, including chronic 
heart failure (20, 21), cancer (22), and obstructive pulmonary dis-
ease (23). Importantly, the molecular mechanisms involved in 
CKD-related muscle wasting have not been fully elucidated, and 
their characterization is essential for the development of novel 
therapeutic strategies.
This study represents a most comprehensive multidimen-
sional characterization of muscle wasting in the context of CKD. 
Our findings unravel a potentially new kidney/muscle axis linking 
CKD to an increased production of multiple pro-cachectic factors, 
including activin A, which accumulate in the blood of 3 experimen-
tal mouse models and samples from human patients with CKD, 
resulting in skeletal muscle wasting. This process is exacerbated 
by a diminished capacity of kidney filtration and, thereby, reduced 
clearance of circulating activin A. Pharmacological blockade of 
activin A as well as downregulation of its receptor ACVR2A/B in 
the muscle were sufficient to overcome all other regulated sig-
nals, and to normalize muscle molecular profiles, suggesting that 
activin A is a central factor in CKD-induced cachexia and providing 
a promising therapeutic target. In summary, we have identified and 
characterized a potentially novel molecular crosstalk between kid-
ney and muscle that may pave the way for pharmacological modu-
lation of skeletal muscle wasting in patients with CKD.
Results
Kif3aΔTub mice develop CKD and cachexia with skeletal muscle atro-
phy and muscle weakness. We used a genetic mouse model of CKD 
where the kinesin family member 3A (Kif3a) alleles were deleted 
in renal tubular epithelial cells (24). Tubular Kif3a deficiency 
(Kif3aΔTub) led to spontaneous renal cyst formation that almost 
completely replaced the normal renal parenchyma by 6 weeks 
of age (Figure 1A). Kidneys from Kif3aΔTub mice showed substan-
tial enlargement, accounting for approximately 20% of total 
body weight (Figure 1B). Histological staining showed big cysts, 
dilated tubules, and only a handful of surviving glomeruli in Kif3aΔTub 
kidney compared with wild-type (WT) mice (Supplemental Fig-
ure 1A; supplemental material available online with this article; 
https://doi.org/10.1172/JCI135821DS1), which was reflected in a 
significant loss of renal function (Figure 1C). These findings sup-
port that Kif3aΔTub mice showed functional and structural signs 
consistent with advanced CKD.
Interestingly, despite the dramatic increase in kidney size, 
Kif3aΔTub mice presented significant weight loss (Figure 1D). Sys-
tematic analysis of 4 skeletal muscles, including gastrocnemius 
(GC), tibialis anterior (TA), extensor digitorum longus (EDL), 
and soleus, showed a significant weight reduction in Kif3aΔTub 
compared with WT mice (Figure 1, E and F). Furthermore, we 
observed a reduced number of fibers in EDL and soleus muscles 
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only in cells from the JGA (Figure 3, E and F and Supplemental 
Figure 3A). Furthermore, publicly available single-nucleus RNA- 
sequencing data on fibrotic kidneys from mice 14 days after uni-
lateral ureteral obstruction surgery (27) supported our finding that 
Inhba was expressed in a subpopulation of fibroblasts (Act. Fib1) 
and in cells from the JGA (Supplemental Figure 3, B and C). Effec-
tive kidney production of activin A would need to be reflective of 
increased circulating levels. Indeed, we found that blood levels of 
activin A were significantly elevated in Kif3aΔTub compared with 
WT mice (Figure 3G).
Overall, these findings suggest that the kidney source of Inhba 
is a subpopulation of fibroblasts and cells from the JGA, which are 
expanded during the development of kidney fibrosis.
Activin A is increased in patients with CKD. To validate our 
findings from our experimental model of CKD, we analyzed the 
blood levels of activin A in a first cohort of patients diagnosed 
with different glomerulonephritis at different stages of CKD 
(n = 75; Supplemental Figure 4A). Patients with CKD had signifi-
cantly higher blood levels of activin A compared with healthy 
controls (n = 23; Figure 4A). Blood levels of activin A strongly 
correlated with estimated glomerular filtration rate (eGFR; R = 
–0.56, P < 0.0001; Figure 4B).
A unifying pathological feature of CKD is the develop-
ment of tubulointerstitial fibrosis. As expected, the percentage 
of tubulointerstitial fibrosis was inversely associated to eGFR 
(R = –0.46; P < 0.0001; Figure 4C), while the levels of activin 
A were directly associated with the percentage of tubulointersti-
ofibrillar locations was decreased in muscles from Kif3aΔTub mice, 
mitochondria also appeared enlarged (Figure 2F). Furthermore, 
muscles from Kif3aΔTub mice showed a significant increase in the 
expression of key genes involved in the oxidative stress and mito-
chondrial unfolded protein response (UPRmt; Figure 2G).
Increased kidney production of pro-cachectic factors in CKD-re-
lated muscle wasting. In light of a potential crosstalk between 
kidney and muscle during CKD, the production of renal soluble 
factors with known pro-cachectic effects was investigated. First, 
we performed microarray analysis of gene expression in kidneys 
from WT and Kif3aΔTub mice and identified 9 genes with pro- 
cachectic potential (Figure 3A). From these genes, we decided to 
focus on inhibin beta-A (Inhba), which encodes activin A, based 
on its key role as a negative regulator of skeletal muscle mass (18, 
19). Next, we checked if the increase of Inhba specifically occurred 
in the kidney. Interestingly, we found that upregulation of Inhba 
occurred specifically in the kidney and not in other tissues, such as 
muscle, liver, and heart (Figure 3B).
To identify the cell population expressing Inhba in the kidney, 
we performed single-cell RNA sequencing on 5-week-old Kif3aΔTub 
and control kidneys. A total of 6779 cells were profiled after data 
preprocessing and quality controls and classified into 17 distinct 
cell types in the Kif3aΔTub kidney (Figure 3C). We found that Inhba 
was expressed in a subpopulation of fibroblasts (reference name: 
Fib-2), which was only found in the Kif3aΔTub kidney, and in cells 
from the juxtaglomerular apparatus (reference name: JGA) (Fig-
ure 3D). In the control kidney, we found the expression of Inhba 
Figure 1. Experimental CKD induces loss of muscle mass and function. (A) Schematic representation of cystic mouse model. (B) Kidney weight/body 
weight expressed as a percentage and a representative image of the 6-week kidney of WT and Kif3aΔTub (n = 5 mice). (C) Blood urea nitrogen (BUN) mea-
surement (n = 5 mice). Body weight (D) (n = 10 mice) and muscle tissue weights (E) were measured in WT and Kif3aΔTub mice (n = 14 mice). (F) Represen-
tative image of the 6-week GC muscle of WT and Kif3aΔTub mice. (G) Frequency histogram showing the distribution of cross-sectional areas (μm2) in TA 
muscle of WT and Kif3aΔTub mice (n = 3 mice). (H) Contractile properties of the EDL muscle (n = 5 mice). Specific force denotes tetanic force normalized to 
wet muscle mass. Data shown as mean ± SEM of 3 independent experiments. Student’s t test used for statistical significance. *P < 0.05, ***P < 0.001. 
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22,268 cells that covered the entire nephron segment along with 
endothelial and immune cells. Single-cell data showed that INHBA 
was mainly expressed in vascular smooth muscle/mesangial cells 
and in this case parietal epithelial cells (Figure 4H). Collectively, 
these findings suggest a higher renal production of pro-cachectic 
factor activin A in patients with CKD.
Activin A–mediated muscle wasting in other models of experi-
mental CKD. Given that patients develop CKD due to multiple 
underlying causes, it is important to explore other experimen-
tal models of CKD, especially those with a strong fibrosis com-
ponent. First, we used a mouse model of 2,8-DHA–induced 
nephropathy (adenine nephropathy, AN). By 21 days adenine- 
enriched diet led to progressive kidney disease, characterized by 
crystal deposits, tubular injury, inflammation, and tubulointer-
stitial fibrosis (refs. 29, 30; Figure 5, A and B; and Supplemental 
Figure 5A). Mice with AN had significant weight and lean mass 
loss over time (Figure 5, C and D).
Systematic analysis of 4 skeletal muscles, including GC, TA, 
EDL, and soleus, showed a significant reduction of muscle weight 
in AN compared with WT mice (Figure 5E and Supplemental 
Figure 5B). Quantification of cross-sectional area of TA muscles 
showed a leftward shift at the terminal time point in AN compared 
with WT (Figure 5F), resulting in a large decrease in the average 
tial fibrosis (R = 0.35; P < 0.01; Figure 4D). These data suggest 
that interstitial fibrosis may lead to an increased production of 
activin A in human CKD, linked to high circulating levels due to 
progressive blood accumulation that is potentially amplified by 
impaired renal function.
Increased production of pro-cachectic factors in patients with 
CKD. In a second cohort of patients with CKD at different stages 
of CKD (n = 194), we analyzed gene expression profiles of human 
kidney biopsies (Supplemental Figure 4B). Gene expression analy-
sis was performed on microdissected glomerular and tubulointer-
stitial compartments as previously described (28). mRNA expres-
sion of INHBA, nuclear factor κB1 (NFKB1), CXCL13, and IL-1b 
was increased in patients with CKD (Figure 4E and Supplemental 
Figure 4C). Furthermore, mRNA expression of INHBA showed a 
significant inverse correlation with eGFR (R = –0.39, P < 0.0001; 
Figure 4F). Next, we analyzed a third cohort of human kidney 
biopsies from patients with focal segmental glomerulosclerosis 
(FSGS; n = 66; Supplemental Figure 4D). mRNA expression of 
INHBA, GDF15, IL-1b, NFKB1, CXCL13, and IL-6 showed signifi-
cant inverse correlations with eGFR (Figure 4G and Supplemental 
Figure 4, E and I). Unsupervised cluster analysis of single-cell data 
in the Kidney Precision Medicine Project reference single-cell 
RNA-sequencing (scRNA-Seq) data set yielded 31 clusters from 
Figure 2. Characterization of CKD-related muscle wasting. (A) Quantification of satellite cell number on freshly isolated EDL fibers (n = 2 mice). (B) Pro-
filing of differentiation (WT n = 20, Kif3aΔTub n = 20). (C) Quantification of puromycin incorporation in GC muscle from 6-week-old WT and Kif3aΔTub mice, 
using in vivo SUnSET technique (WT n = 20, Kif3aΔTub n = 20). (D) Autophagy flux analysis with colchicine treatment based on immunoblot analysis of p62 
and LC3 of protein extracts from of GC muscles from fed and starved 6-week-old WT and Kif3aΔTub mice (n = 3 mice). (E) SDH staining and quantification 
of EDL muscles of WT and Kif3aΔTub mice (n = 3 mice). (F) Quantification of SS and intermyofibrillar (IMF) mitochondrial density and size. One-way ANOVA 
followed by Bonferroni’s multiple-comparison tests (SS: WT n = 4, Kif3aΔTub 8; IMS: WT n = 8, Kif3aΔTub 13). (G) Quantitative gene expression of oxidative 
stress/UPRmt genes in GC muscle from 6-week-old WT and Kif3aΔTub mice (n = 4 mice). Data shown as mean ± SEM. Student’s t test used for statistical 
significance, unless otherwise stated. Comparisons of more than 2 groups were calculated using 1-way ANOVA with Tukey’s multiple-comparison tests.  
*P < 0.05; **P < 0.01; ***P < 0.001; ns, not statistically significant.
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tal Figure 6C). Importantly, AS mice showed increased blood 
levels of activin A compared with WT (Supplemental Figure 6D). 
At this stage of CKD, there were classical histopathological 
changes and significant deposition of collagen III and IV (Sup-
plemental Figure 6, G and H).
Collectively, these findings confirm that the increase of blood 
levels of activin A is a general response to tubulointerstitial fibrosis 
during the development of CKD.
Pharmacological inhibition of activin A prevents muscle wasting 
in experimental CKD. Since increased blood levels of activin A are 
a hallmark of CKD in both mice and humans, we decided to test a 
pharmacological approach to modulate activin A signaling in vivo 
using a soluble activin receptor type IIB ligand trap (sActRIIB).
Kif3aΔTub and WT mice received sActRIIB twice a week by 
intraperitoneal injections (10 mg/kg) starting at 2 weeks of age for 
4 consecutive weeks (Figure 6A). Treatment with sActRIIB pre-
vented body weight loss in Kif3aΔTub mice (Figure 6B). The weights 
of all analyzed muscles in sActRIIB-treated Kif3aΔTub mice were 
similar to or even greater than those of WT mice (Figure 6C and 
Supplemental Figure 7, A and B). Interestingly, the total fiber num-
ber loss in EDL muscles was not prevented by sActRIIB (Figure 
6D). Quantification of cross-sectional area of TA muscle showed 
that in mice treated with sActRIIB, fiber sizes were broadly distrib-
uted compared with Kif3aΔTub mice (Figure 6E), resulting in a large 
fiber size (1539 μm2 in WT vs. 1054 μm2 in AN). Electron micros-
copy revealed a disorganized sarcomere arrangement with Z-disk 
misalignment, empty spaces between myofibrils, and dilated 
endoplasmic reticulum (Figure 5G). Mitochondrial density in both 
SS and IMF locations was decreased in muscles from AN com-
pared with WT and was associated with mitochondrial enlarge-
ment (Figure 5H). Furthermore, gene expression analysis in mul-
tiple organs of AN mice revealed an almost exclusive upregulation 
of mRNA levels of Inhba in the kidney rather than in other tissues, 
such as muscle, liver, and heart (Figure 5I). Fluorescence in situ 
hybridization (FISH) supported increased expression of Inhba in 
the kidney of AN mice compared with WT (Figure 5J). We found a 
significant increase in gene expression of Acvr2a and Acvr2b in the 
TA muscles of AN mice, suggesting that this pathway is a direct 
target of activin A (Supplemental Figure 5C). As expected, blood 
levels of activin A were also significantly elevated in AN compared 
with WT mice (Figure 5K).
In addition, we also examined a mouse model of Alport syn-
drome (AS), which is characterized by an altered composition 
of the glomerular basement membrane that ultimately results 
in loss of renal function (31). We analyzed tissues from AS 
mice within the first 8 weeks of life (Supplemental Figure 6A), 
which already showed significant kidney function impairment 
(Supplemental Figure 6B) and loss of body weight (Supplemen-
Figure 3. Experimental CKD leads to renal production of soluble pro-cachectic factors. (A) Volcano plot of genes encoding for secreted proteins (red, 
genes encoding pro-cachectic factors) (n = 4 mice). (B) Quantitative reverse transcription PCR (RT-PCR) analysis of Inhba in different organs (n = 4 mice). 
(C) t-Distributed stochastic neighbor embedding (t-SNE) projection of 6779 cells from the 5-week Kif3aΔTub kidney demonstrating 17 cell types. (D) t-SNE 
plot showing the normalized/average expression level of Inhba in Kif3aΔTub kidney cell types. (E) Dot plot showing the expression of Inhba in the Kif3aΔTub 
and control kidney. (F) Violin plot showing cluster-specific gene expression of Inhba (n = 1 mouse). (G) Blood levels of activin A in WT and Kif3aΔTub mice 
determined by ELISA (WT n = 3, KO n = 5). Data shown as mean ± SEM. Student’s t test used for statistical significance, unless otherwise stated. *P < 
0.05, **P < 0.01, ***P < 0.001.
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increase in the average fiber size (1074 μm2 in WT vs. 661 μm2 
in Kif3aΔTub vs. 1402 μm2 in sActRIIB-treated Kif3aΔTub). Further-
more, the increase in fiber cross-sectional area in sActRIIB-treat-
ed Kif3aΔTub mice was confirmed in all fiber types irrespective of 
their MHC expression (Supplemental Figure 7, C and D). Treat-
ment with sActRIIB normalized the number of muscle stem cells 
(Figure 6F) but did not impact their differentiation potential 
(Supplemental Figure 7E). Importantly, treatment with sActRIIB 
increased EDL tetanic and specific force in Kif3aΔTub mice (Figure 
6G and Supplemental Figure 7F).
Next, we evaluated the role of sActRIIB treatment on muscu-
lar metabolic status. Treatment with sActRIIB did not significantly 
alter the portion of oxidative fibers in EDL and soleus of Kif3aΔTub 
compared with WT mice (Supplemental Figure 7, G and H). Mito-
chondrial density in both SS and IMF locations showed a slight 
increase in Kif3aΔTub mice after sActRIIB treatment (Figure 6H). 
This observation was consistent with an increased expression of 
genes encoding RCC subunits and fatty acid oxidation, which gen-
erates direct substrates for electron transport and ATP production 
(Supplemental Figure 7, I and J). The number of enlarged mito-
chondria in Kif3aΔTub mice was significantly reduced after sAct-
RIIB treatment (Figure 6H), which correlated with a decrease in 
expression of key genes involved in the UPRmt (Figure 6I).
In Kif3aΔTub mice, sActRIIB administration decreased levels 
of free activin in circulation (Figure 7A), and other pro-cachectic 
factors (Figure 7B), for example IL-6 and glucocorticoids. Treat-
ment with sActRIIB restored AKT/mTOR signaling (Figure 7, C 
and D) and led to an increase in the protein synthesis that was 
previously impaired in Kif3aΔTub mice (Figure 7E). Treatment with 
sActRIIB also prevented activation of the activin A/p38 MAPK 
signaling pathway (Figure 7F), which contributes to protein deg-
radation in skeletal muscle (32). Next, we examined the regula-
tion of forkhead box protein O (FoxO), a downstream target of 
glucocorticosteroids (Supplemental Figure 8A), which is consid-
Figure 4. Increased production of pro-cachectic factors in patients with CKD. (A) Activin A blood level in healthy controls and in patients with CKD (n = 
75 patients). (B) Spearman’s correlation analysis of serum activin A and eGFR. **P < 0.01. (C) Spearman’s correlation analysis of IF/TA% (renal interstitial 
fibrosis and tubular atrophy) and eGFR. (D) Spearman’s correlation analysis of serum activin A and IF/TA% (renal interstitial fibrosis and tubular atrophy). 
(E) Log fold change of quantitative gene expression of genes encoding pro-cachectic factors in glomeruli of manually microdissected biopsies from 
patients with different CKD stages (Glomerular: CKD1: n = 55; CKD2: n = 52; CKD3: n = 44; CKD4: n = 26; CKD5: n = 10. Tubular: CKD1: n = 56; CKD2: n = 46; 
CKD3: n = 37; CKD4: n = 26; CKD5: n = 10. Live donor: n = 42). A q value below 5% was considered statistically significant. Nonsignificantly changed genes 
are denoted as ns and genes below background cutoff as BC. GDF15, growth differentiation factor 15. (F) Spearman’s correlation analysis for glomerular 
activin A mRNA expression with eGFR. (G) Spearman’s correlation analysis of patients with focal segmental glomerulosclerosis (FSGS) of INHBA mRNA 
expression with log2eGFR (n = 66 patients). (H) Dot plot shows the relative average mRNA expression of INHBA across the 31 clusters identified from the 
combined analysis of the 24 adult human kidney scRNA-Seq data sets.
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Figure 5. Skeletal muscle atrophy and accumulation of activin A in the blood are common features of different models of kidney fibrosis. (A) Schematic 
representation of 2,8-DHA nephropathy model (AN): mice are fed for 21 days with adenine-enriched diet. (B) BUN measurement (n = 5 mice). (C) Body weight 
(D) and lean mass curve in WT and AN mice (n = 5 mice). (E) GC muscle weights (n = 5 mice). (F) Frequency histogram showing the distribution of cross- 
sectional areas (μm2) in TA of WT and AN mice (n = 4 mice). (G) Electron micrographs of EDL muscles of WT and AN mice. Scale bar: 2 μm. (H) Quantification 
of SS and IMF mitochondrial density and size. One-way ANOVA followed by Bonferroni’s multiple-comparison tests. (I) Quantitative RT-PCR analysis of Inhba 
in different organs (n = 5 mice). (J) In situ hybridization was performed with an RNAscope probe targeting Inhba mRNA. Representative images of WT and AN 
kidney. Inhba mRNA shown in green and nuclei counterstained with DAPI (blue). Scale bars: 10 μm. (K) Blood levels of activin A in WT and AN mice determined 
by ELISA (n = 5 mice). Values are mean ± SEM. Student’s t test used for statistical significance, unless otherwise stated. *P < 0.05, **P < 0.01, ***P < 0.001.
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organs (Supplemental Figure 8C) as well as GDF8 blood levels 
were not changed in Kif3aΔTub compared with WT mice (Supple-
mental Figure 8D), suggesting a specific role of activin A in pro-
moting muscle wasting in CKD-induced cachexia that can be 
pharmacologically targeted.
In vivo blockade of activin A attenuates experimental CKD. Admin-
istration of sActRIIB significantly reduced kidney/body weight ratios 
in Kif3aΔTub mice (Supplemental Figure 9A), showing a partial protec-
ered a central regulator of muscle homeostasis (26, 33, 34). We 
found an increase in both gene expression and protein level of 
FOXOs that were diminished by sActRIIB treatment (Figure 7G), 
resulting in a downregulation of FoxO-dependent gene transcrip-
tion (Supplemental Figure 8B) and the restoration of normal lev-
els of autophagy (Figure 7H). It is also worth noting that ActRIIB 
signals through a subset of TGF-β family ligands, including myo-
statin (35, 36). Importantly, mRNA levels of myostatin in multiple 
Figure 6. Pharmacological inhibition of activin A prevents muscle wasting in experimental CKD. (A) Schematic representation of experimental design: 
treatment of WT and Kif3aΔTub mice twice weekly by intraperitoneal (i.p.) injections of vehicle treatment or 10 mg/kg sActRIIB starting at 2 weeks of age 
for 4 weeks. (B) Left panel: representative image of 6-week-old body size of WT, Kif3aΔTub, and Kif3aΔTub sActRIIB mice. Right panel: growth curve of WT, 
Kif3aΔTub, and Kif3aΔTub sActRIIB mice (n = 5 mice). (C) GC weight of WT, Kif3aΔTub, and Kif3aΔTub sActRIIB mice (n = 13 mice). (D) Analysis of the number of 
fibers per muscle in WT and Kif3aΔTub mice and Kif3aΔTub sActRIIB mice (n = 3 mice). (E) Frequency histogram showing the distribution of cross-sectional 
areas (μm2) in TA of WT, Kif3aΔTub, and Kif3aΔTub sActRIIB mice (n = 3 mice). (F) Quantification of satellite cell number on freshly isolated EDL fibers in WT 
and Kif3aΔTub mice and Kif3aΔTub sActRIIB mice (n = 2 mice). Data of WT and Kif3aΔTub have already been presented in Figure 2B. (G) Tetanic specific force 
measurement in EDL muscle of WT and Kif3aΔTub mice and Kif3aΔTub sActRIIB mice. Data of WT and Kif3aΔTub have already been presented in Figure 1H (n 
= 5 mice). (H) Quantification of SS and IMF mitochondrial density and size. One-way ANOVA followed by Bonferroni’s multiple-comparison tests. Data of 
WT and Kif3aΔTub have already been presented in Figure 2F (n = 3 mice). (I) Quantitative gene expression of UPRmt genes in GC muscle from 6-week-old WT, 
Kif3aΔTub, and Kif3aΔTub sActRIIB mice (n = 4 mice). Data shown as mean ± SEM of 3 independent experiments. Comparisons of more than 2 groups were 
calculated using 1-way ANOVA with Tukey’s multiple-comparison tests: *when comparing WT vs. Kif3aΔTub, §when comparing WT vs. Kif3aΔTub sActRIIB,
#when comparing Kif3aΔTub vs. Kif3aΔTub sActRIIB. *,§,#P < 0.05, **,§§P < 0.01, ***,§§§,###P < 0.001. 
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Discussion
The communication between different tissues is a key evolutionary 
feature of complex organisms (37). There are numerous examples 
where a disease that develops in one organ leads to the functional 
failure of others via a crosstalk mediated by soluble factors (12, 
38–42). As CKD develops and progresses, other organs, including 
the liver, vasculature, lung, and heart, are also directly affected 
(43–45). Here, we identified, likely for the first time, a crosstalk 
between kidney and muscle, confirming the central role of the kid-
ney as a master regulator of interorgan signaling (Figure 9).
Multiple studies have shown how muscle wasting is often the 
result of dysregulated protein synthesis, proteasomal activity, 
and autophagy (13). To our knowledge, this is the first time that 
skeletal muscle wasting has been systematically and thoroughly 
characterized in experimental CKD, showing that attenuated 
muscle growth depends on reduced rate of protein synthesis, as 
well as increased protein breakdown mediated by high autophagy 
flux. These findings were also supported by quantitative and qual-
itative alterations of specific muscle force, which clearly suggest 
functional impairment. Recent studies have shown in experimen-
tal models (46) and patients with CKD (47) that presence of mus-
cle fibrosis correlates inversely with muscle function. While we 
did not observe an overt increase in muscle fibrosis to explain the 
loss of specific force in experimental CKD, we identified changes 
in the organization and density of subcellular organelles such as 
mitochondria, as in previous reports in aged rodents (48).
Renal interstitial fibrosis is considered the ultimate end point 
of all diseases leading to CKD (49), irrespective of their initial 
etiology, leading to irreversible loss of kidney function (50, 51). 
Transdifferentiation of fibroblasts/pericytes into myofibroblasts 
has been previously described as a key element of the profibrotic 
processes (52–56). Importantly, transcriptional profiles of myofi-
broblasts during renal fibrosis show, among the most upregulated 
genes, Inhba (57), which encodes the secreted protein activin 
A that acts both as a growth and differentiation factor (58, 59) 
and is a potent inhibitor of muscle growth (35, 60). Here, we 
showed that, both in experimental mouse models and in humans, 
increased production of activin A occurs specifically in kidneys in 
response to CKD.
Increased circulating pro-cachectic factors (e.g., activin A) 
have been observed in patients with cancer (22, 61), in patients 
with chronic obstructive pulmonary disease (23), and now in 
patients with CKD. Furthermore, our findings also suggest that 
blood levels of activin A increased with the progression of renal 
impairment. For this reason, we propose that there is a double hit 
effect during CKD with increased production of activin A and ele-
vated circulating levels, which are exacerbated by impaired kidney 
clearance. Therefore, the inactivation of circulating pro-cachectic 
signals, or a direct inhibition of ActRIIB signaling directly in mus-
cle, may be an efficient therapeutic intervention.
Indeed, our data show that a pharmacological approach, 
using the sActRIIB, successfully prevented muscle loss in exper-
imental CKD, normalizing muscle force as well as mitochondrial 
mass, localization, and function. This was also confirmed by the 
normalization of protein synthesis and the expression of genes 
regulating proteasome-mediated protein degradation and auto-
phagy. Administration of soluble ActRIIA/B blocking antibodies 
tion from cyst formation (Supplemental Figure 9B), which attenuated 
the expected loss of kidney function (Supplemental Figure 9C).
Ultrastructural analyses revealed extensive cell death in 
proximal tubuli and numerous large cysts surrounded by a flat 
epithelium in untreated Kif3aΔTub mice, all of which were par-
tially averted by sActRIIB (Supplemental Figure 9D). Further-
more, sActRIIB treatment prevented mitochondrial alterations 
(Supplemental Figure 9E), and reductions in the levels of RCC 
proteins, including translocase of outer membrane 20 and per-
oxisome proliferator–activated receptor γ coactivator 1-α (Sup-
plemental Figure 9F).
In vivo targeting of activin A signaling in muscle prevents CKD- 
induced skeletal muscle wasting. To determine whether blocking 
activin A signaling directly in the muscle is sufficient to rescue 
muscle mass in the context of ongoing experimental CKD, we 
used recombinant serotype 6 adeno-associated virus vectors to 
downregulate the activin A receptor (ACVR2A/B) in a specific 
muscle before the induction of AN (Figure 8A and Supplemental 
Figure 10A). Adenine diet led to progressive kidney disease char-
acterized by inflammation and tubulointerstitial fibrosis (Figure 
8B) and upregulation of mRNA levels of Inhba in the kidney (Fig-
ure 8C). This led to increased circulating levels of activin A (Figure 
8D) and loss of body weight (Figure 8E).
Muscles were analyzed 21 days after the adenine diet was 
started and viruses injected. Administration of (AAV-)Acvr2a/
b-shRNA resulted in a downregulation of 40% to 50% of the 
Acvr2a/b expression in the TA muscle of WT and AN mice (Sup-
plemental Figure 10B) compared with those injected with (AAV-)
Scramble-shRNA. Downregulation of ActRIIB/A signaling in 
TA muscles was sufficient to limit muscle mass loss in AN mice 
(Figure 8F). Differences in myofiber size between (AAV-)Acvr2a/ 
b-shRNA and (AAV-)Scramble-shRNA were consistent with the 
proportional differences in muscle mass observed in the same 
conditions (Figure 8G). No difference was observed in muscle 
weight and fiber size of WT mice upon (AAV-)Acvr2a/b-shRNA 
injection compared to scramble.
Together, these results supported a protective effect of 
muscle-specific activin A signaling downregulation, despite high 
levels of circulating activin A and severely affected renal function.
Figure 7. Pharmacological inhibition of activin restores protein synthesis 
while inhibiting protein breakdown. (A and B) Activin A, IL-6, and corti-
costerone blood level determined by ELISA in WT, Kif3aΔTub, and Kif3aΔTub 
sActRIIB mice. A: WT n = 3, Kif3aΔTub n = 5, Kif3aΔTub sActRIIB n = 5.
B left panel: WT n = 4, Kif3aΔTub n = 4, Kif3aΔTub sActRIIB n = 4.
B right panel: WT n = 10, Kif3aΔTub n = 8, Kif3aΔTub sActRIIB n = 10. (C and 
D) Total protein extracts from muscle of 6-week-old WT, Kif3aΔTub, and 
Kif3aΔTub sActRIIB mice were immunoblotted with the indicated anti-
bodies (n = 3 mice). (E) Quantification of puromycin incorporation in GC 
muscle from 6-week-old WT Kif3aΔTub and Kif3aΔTub sActRIIB mice, using 
in vivo SUnSET technique (n = 3 mice). (F and G) Total protein extracts 
from muscle of 6-week-old WT, Kif3aΔTub, and Kif3aΔTub sActRIIB mice were 
immunoblotted with the indicated antibodies (n = 3 mice). (H) Autophagy 
flux analysis with colchicine treatment. Immunoblot analysis of p62 and 
LC3 of protein extracts from GC muscles from fed and starved 6-week-old 
WT, Kif3aΔTub, and Kif3aΔTub sActRIIB mice (n = 3 mice). Values are mean 
± SEM. Comparisons of more than 2 groups were calculated using 1-way 
ANOVA with Tukey’s multiple-comparison tests. *P < 0.05, **P < 0.01, 
***P < 0.001. In H, only statistically significant comparisons are shown.
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mechanisms inducing hypertrophy, which could blur our conclu-
sions. Furthermore, the amelioration of muscle wasting was inde-
pendent of severe kidney disease and occurred despite elevated 
circulating levels of pro-cachectic ligands. Thus, these results 
demonstrate the utility of our approach for dissociating such 
ligands from their effects on intracellular signaling processes that 
promote muscle wasting.
To our knowledge, this is the first study to investigate the 
effect of the downregulation of both Acvr2b and Acvr2a in adult 
mice. Indeed, a recent study (69) showed how targeting the 
Acvr2b and Acvr2a in muscle leads to muscle hypertrophy. In this 
paper, the authors used a myosin light chain promoter/enhancer 
that leads to the deletion of the Acvr2b and Acvr2a from E13 days, 
which may have impacted muscle development from an embry-
onic stage. In contrast, we used a system where we downregulate 
the Acvr2b and Acvr2a in the muscle of adult mice, excluding the 
possibility of compensatory hypertrophy. We propose that similar 
strategies could be engineered in the future in order to limit the 
risk of off-target effects.
Muscle wasting in CKD is the consequence of a complex inter-
play of different factors that induces systemic and multiorgan 
complication (70). We hypothesize that, while the initial source 
of the pro-cachectic and proinflammatory molecules is the kid-
ney, other organs play a critical role in regulating the anabolic/
has already been used in preventing muscle wasting in different 
mouse models of glucocorticoid-induced atrophy (62), of micro-
gravity (63), and of sarcopenia (64) and in cancer-associated 
cachexia (61, 65).
Based on these findings, activin A blockade could be consid-
ered as a potential clinical pharmacological intervention in CKD 
patients with skeletal muscle wasting. While different soluble 
receptor ligand traps are being actively tested in various clinical 
trials (66, 67), broad tissue expression of ActRIIB and its pro-
miscuous TGF-β superfamily ligands reduce the interest in using 
ligand-trapping approaches directed at ActRIIB (68). Indeed, we 
showed that ligand trap treatment has a direct effect in the atten-
uation of kidney pathology. Given that kidney function affects the 
levels of circulating factors (i.e., loss of renal function may lead 
to an accumulation in blood) — then improving renal function 
could simply further reduce circulating levels of activin A, which 
should also prevent muscle wasting. For this reason, we consid-
ered a different approach based on viral targeting. We demon-
strated that attenuating ActRIIB/A intramuscular signaling with 
a tissue-specific (AAV-)Acvr2a/b-shRNA is an effective tool to 
reduce muscle wasting associated with CKD. In addition, we pro-
vide data in control mice, showing no difference in muscle weight 
and cross-sectional area between those injected with Scramble or 
Actr2a/b-shRNA, thus ruling out the possibility of compensatory 
Figure 8. Muscle-specific downregulation of activin pathway protects from CKD-induced skeletal muscle atrophy. (A) Schematic representation of 
experimental design: mice were fed with adenine-enriched diet to induce 2,8-DHA nephropathy (AN), and TA muscles were transfected with (AAV-) 
Acvr2a/b-shRNA or (AAV-)Scramble-shRNA. Muscles were examined 3 weeks later. (B) Representative images of the renal histology of WT and AN kid-
ney. Scale bars represent 60 μm. PAS, periodic acid–Schiff. (C) Quantitative RT-PCR analysis of Inhba in kidneys of WT and AN mice (n = 4 mice). (D) Blood 
levels of activin A in WT and AN mice determined by ELISA (n = 4 mice). (E) Body weights were measured in WT and AN mice (n = 7 mice). (F) The weight 
of (AAV-)Acvr2a/b-shRNA– and (AAV-)Scramble-shRNA–infected muscles of WT and AN mice were measured (n = 4 mice). (G) Average fiber cross- 
sectional area of TA muscle of WT and AN mice infected with (AAV-)Acvr2a/b-shRNA or (AAV-)Scramble-shRNA (n = 3 mice). Data shown as mean ± 
SEM. Student’s t test used for statistical significance. *P < 0.05, **P < 0.01, ***P < 0.001. 
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Acvr2a-shRNA (shRNA1 from knockdown efficiency validation) for-
ward primer: 5′-GATCCGCTAGAGGATTGGCATATTTACTCGAG-





(shRNA1 from knockdown efficiency validation) reverse primer: 
5′-CTAGAAAAAAGGGAGTGCATCTACTACAACGCTCGAGC-
GTTGTAGTAGATGCACTCCCG-3′.
A total of 6 × 105 HEK293T/17 cells (ATCC CRL-11268) were 
seeded in each well of 6-well plates and incubated overnight at 37°C 
in a humidified incubator containing 5% CO2 to achieve approx-
imately 70% to 80% confluence. Each well was cotransfected by 
0.5 μg plasmid encoding ACVR2A-HA (Addgene plasmid 11754) or 
ACVR2B-MYC, which was generated by modification of ACVR2B 
(Addgene plasmid 13501) with a MYC tag before the stop codon of the 
ACVR2B gene, and 1.5 μg plasmids expressing either shRNA control 
or different shRNA using PolyFect Transfection Reagent (QIAGEN), 
following the manufacturer’s instructions. The transfected cells were 
incubated at 37°C for 24 hours before harvesting for protein analysis.
AAVs were produced by cotransfection of HEK293T/17 cells 
(ATCC CRL-11268) with AAV-shRNA vectors and the packaging/
helper plasmid pDGM6 (Addgene, plasmid 110660), which includes 
the AAV2 rep genes, AAV6 cap genes, and adenovirus helper genes 
(74). Three days after transfection, cell lysates were subjected to 
freeze-thaw cycles in PBS-MK (1× PBS, 1 mM MgCl2, 2.5 mM KCl), and 
the vectors were purified by iodixanol gradient ultracentrifugation fol-
lowed by dialysis and concentration against PBS using centrifugal fil-
ters (Sartorius Vivaspin 20 Centrifugal Concentrators, PES Membrane 
10,000 Da). Physical particles were quantified by real-time PCR (75), 
and titers are expressed as viral genomes per milliliter (vg/mL).
AAV injection. TA muscles of 3-month-old BALB/c mice were 
injected with (AAV-)Acvr2a/b-shRNA while contralateral muscles 
received (AAV-)Scramble-shRNA, and mice were fed with adenine- 
enriched diet. (n = 4 for each condition.)
(AAV-)Acvr2a-shRNA and (AAV-)Acvr2b-shRNA were mixed 
with 5× 109 vg from each and used at 10 × 109 vg in total; (AAV-) 
Scramble-shRNA was used at 10 × 109 vg.
Transcriptome analysis. RNA was purified using standard proce-
dures and analyzed using Affymetrix Mouse Genome 430 2.0 gene 
chips. Raw data were obtained by standard array hybridization tech-
catabolic balance in the muscle. In this context, the central ner-
vous system might contribute to the integration of inflammatory 
signals by increasing the circulating levels of glucocorticoids (71). 
Furthermore, the accumulation of uremic toxins in the body under 
CKD could contribute to muscle loss (72, 73). However, our study 
shows that the muscle wasting actions of other pro-cachectic cyto-
kines (IL-6, corticosterone) are overtaken by the modulation of 
activin A, suggesting that activin A signaling is a dominant step in 
CKD-induced cachexia.
In conclusion, we propose a model where soluble pro- 
cachectic factors accumulated in the blood in response to kidney 
injury, disrupting homeostasis and inducing skeletal muscle wast-
ing. This process can be prevented by attenuating activin A signal-
ing, which offers the potential to effectively prevent CKD-induced 
muscle wasting.
Methods
Animals and treatment. All animals were housed in a specific 
pathogen–free facility with free access to chow and water and a 
12-hour light/12-hour dark cycle. Breeding and genotyping were done 
according to standard procedures. Kif3afl/fl mice were crossed to KspCre 
mice to generate Kif3aΔTub mice (24).
Postnatal myostatin/activin block was induced in 2-week-old 
male mice, through intraperitoneal (i.p.) injection with 10 mg/kg 
of sActRIIB-Fc every week, 2 times till week 6. Blood samples were 
drawn by puncturing the right retro-orbital plexus under isoflurane 
anesthesia. BUN was measured using urea kits (Lehmann) follow-
ing the manufacturer′s instructions. Blood was collected into EDTA 
tubes for ELISA. Activin A (R&D Systems, Bio-Techne; DAC00B), 
IL-6 (R&D Systems, Bio-Techne; MTA00B), corticosterone (Abcam; 
ab108821), and GDF8 (R&D Systems, Bio-Techne; DGDF80) were 
measured following the manufacturers’ instructions.
Mouse model of 2,8-DHA nephropathy. We induced 2,8-DHA 
nephropathy in 12-week-old male mice by administration of a 0.2% 
adenine–containing chow (Altromin) (29, 30).
Construction of the ACVR2A and ACVR2B shRNA and AAV vector 
production. ACVR2A- and ACVR2B-targeting shRNAs were designed 
using the GPP Web Portal (https://portals.broadinstitute.org/gpp/
public/), and AAV-shRNA-ctrl (Addgene plasmid 85741) was used 
as a backbone and control vector. shRNA oligonucleotides were 
subcloned into BamHI and XbaI sites of AAV-shRNA-ctrl to gener-
ate AAV-shRNA-Acvr2a and AAV-shRNA-Acvr2b vectors. We used 
Figure 9. Schematic overview of proposed crosstalk between kidney and muscle during CKD. We propose a new kidney/muscle axis where the soluble 
pro-cachectic factor activin A is produced in injured kidney, accumulates in the blood, and destroys muscle homeostasis and induces muscle wasting.
The Journal of Clinical Investigation   R E S E A R C H  A R T I C L E
1 3J Clin Invest. 2021;131(11):e135821  https://doi.org/10.1172/JCI135821
formed with the Robust Multichip Average method using RMAExpress 
(Version 1.0.5) and the human Entrez Gene custom CDF annotation 
from Brainarray version 18 (http://brainarray.mbni.med.umich.edu/
Brainarray/Database/CustomCDF/genomic_curated_CDF.asp). To 
identify differentially expressed genes, the Significance Analysis of 
Microarrays (SAM) method (81) was applied using SAM function in 
Multiple Experiment Viewer (TiGR MeV, Version 4.9). Correlation of 
eGFR calculated by the CKD Epidemiology Collaboration equation 
(82) was computed with the log-transformed steady-state expres-
sion levels of glomerular gene expression profiles from patients with 
different CKDs.
Single-cell analysis of Kif3aΔTub and control kidneys. A single-cell sus-
pension was prepared using a cold active protease (CAP) as described 
in previous studies (77). Briefly, 1 kidney per mouse was minced into 
pieces on ice, transferred to 2 hard tissue–homogenizing tubes (CK28, 
Precellys, Bertin Instruments) filled with 1 mL ice-cold PBS, and 
homogenized using Minilys (Bertin Instruments) at the highest speed 
for 15 seconds. The homogenized kidney was centrifuged at 400g for 
4 minutes at 4°C. The kidney pellet was suspended in 2 mL red blood 
lysis buffer (R7757, MilliporeSigma) for 2 minutes to remove red blood 
cells. After spin down the kidney pellet was suspended in 2 mL CAP 
solution (10 mg/mL Bacillus licheniformis protease [P5380, Milli-
poreSigma], 5 mM CaCl2, 100 U/mL DNase [04536282001, Roche] 
in PBS) for 20 minutes on ice with repeated trituration steps for 20 
seconds every 5 minutes. The digestion was neutralized by 15 mL 
PBS supplemented with 10% fetal bovine serum and passed through 
a 40 μm Corning cell strainer. Cells were centrifuged at 400g for 4 
minutes at 4°C and washed twice in 20 mL PBS supplemented with 
0.5% bovine serum albumin. Dead cells were removed by Dead Cell 
Removal Kit (130-090-101, Miltenyi Biotec) according to the manu-
facturer’s protocol. The living cells were passed through a 30 μm cell 
strainer (04-004-2326, Sysmex), and cell concentration was deter-
mined using a TC20 automated cell counter (Bio-Rad). Cells were 
loaded on a 10x Genomics Chromium single-cell instrument. All steps 
were performed according to standard protocol of the Chromium 
single-cell 3′ v3 kit to generate high-quality cDNA libraries.
Preprocessing and quality control of scRNA-Seq data. Raw sequenc-
ing data from 10x Genomics were processed using CellRanger soft-
ware (version 3.0.2, 10x Genomics) and the 10x mouse genome 
mm10 3.0.0 release as the reference (function cellranger count). The 
matrices of cells and the unique molecular identifier (UMI) count 
were obtained and further processed by the R package Seurat (version 
3.1.1; ref. 83). As a quality control (QC) step, we first filtered out genes 
detected in fewer than 3 cells and those cells in which fewer than 200 
genes had nonzero counts. To remove potential doublets, cutoff values 
for number of expressed genes (nGene) were determined for samples 
following visual inspection of the distribution of nGene and number 
of UMIs for each cell. The cells with higher nGene values (i.e., 6000) 
were excluded. We further removed low-quality cells with more than 
50% mitochondrial genes of all detected genes (84).
Dimensionality reduction and clustering. The Seurat R package 
(version 3.1.1) was used to perform unsupervised clustering analy-
sis on scRNA-Seq data. In brief, gene counts for cells that passed 
QC were normalized by library size and log-transformed (function 
NormalizeData, normalization.method = “LogNormalize,” scale.
factor = 10,000). Then, highly variable genes were detected (func-
tion FindVariableFeatures, selection.method = “vst,” nfeatures 
niques and normalized via the Single Channel Array Normalization 
algorithm (76) mapping the probes to the custom chip definition file 
from the Brainarray resources in v18.
Raw mapped reads were used to determine differentially 
expressed genes and generate normalized read counts to visualize as 
heatmaps using Morpheus (Broad Institute).
Microarray data on mouse kidney and muscle were deposited in 
the National Center for Biotechnology Information’s Gene Expression 
Omnibus database (GSE169316).
Real-time quantitative PCR. RNA was extracted using QIAzol 
lysis reagent (QIAGEN) according to manufacturer instructions. 
RNA to cDNA conversion was performed using the High Capacity 
cDNA Reverse Transcription Kit (Applied Biosystems, Thermo Fish-
er Scientific). Quantification of target genes was done by quantita-
tive PCR using TaqMan technology (Applied Biosystems, Thermo 
Fisher Scientific). Reaction mixes were run on the QuantStudio 
3 (Applied Biosystems, Thermo Fisher Scientific) thermal cycler. 
TaqMan primer pairs used to quantify target genes were as follows: 
Inhba: Mm00434338_m1; Actb: Mm02619580_ g1; Acvr2a: 
Mm01331097_m1; Acvr2b: Mm00431664_m1; Gapdh: 
Mm99999915_ g1 (Thermo Fisher Scientific).
Kidney tissue profiling from human samples. For bulk mRNA process-
ing, glomerular expression profiles from microdissected kidney tissue 
were generated from participants with biopsy-proven FSGS enrolled 
in NEPTUNE study. RNA-Seq expression data were obtained from 66 
patients with FSGS (77). Briefly, Illumina TruSeq mRNA sample prep 
v2 kit was used to process the mRNA samples. Samples were run on 
Illumina HiSeq2000, paired-end read length of 100 bases at the facil-
ity of University of Michigan Advanced Genomics Core (https:// brcf. 
medicine.umich.edu/cores/advanced-genomics/). Quality of the data 
was assessed using the standard measures using FASTQC tool. Annota-
tion and quantification of mapping results on gene level were performed 
using HTseq (78) and transformed with voom (78). All downstream anal-
yses were performed using the voom-transformed intensities.
Single-cell expression profiling. The Kidney Precision Medicine 
Project (KPMP) adult human kidney reference data set was created 
by the combined analysis of 24 scRNA-Seq data sets, including 
16 tumor nephrectomies, 5 surveillance, and 3 living donor tissue 
biopsies (77). Tissue dissociation into single-cell suspensions was 
accomplished by the enzyme Liberase TL (Roche, 5401020001) at 
37°C for 12 minutes. 10x Genomics technology was used to gener-
ate the single-cell sequencing data. Clustering and the downstream 
analysis of the sequencing data was performed using Seurat (ver-
sion3) R package (79).
Human microarray analysis. Human renal biopsy specimens and 
Affymetrix microarray expression data were obtained within the 
framework of the European Renal cDNA Bank—Kröner-Fresenius 
Biopsy Bank (80). Published data sets of glomerular and tubulointer-
stitial samples from patients with different CKDs were analyzed for 
mRNA expression levels. Analysis included gene expression profiles 
from patients with cadaveric donor, tumor nephrectomy, Antineu-
trophil cytoplasmic antibody–associated glomerulonephritis, lupus 
nephritis, membranous nephropathy, FSGS, IgA nephropathy, dia-
betic nephropathy, hypertensive nephropathy, minimal change dis-
ease, and controls (living donors; GSE99340, GSE32591, GSE35489, 
GSE37463). Grouping of the patients into different CKD stages (CKD 
1–5) was done as published (28). CEL file normalization was per-
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Under circulating oxygenated Krebs solution, one end of a silk 
suture was attached to the distal tendon of the EDL and the other to 
a force transducer (FT03, Grass Instruments). The proximal tendon 
remained attached to the tibial bone. The leg was secured in the exper-
imental chamber. Silver electrodes were positioned on either side of 
the EDL. A constant voltage stimulator was used to directly stimulate 
the EDL, which was stretched to attain the optimal muscle length to 
produce maximum twitch tension. Tetanic contractions were invoked 
by stimulus trains of 500 ms duration at 20, 50, 100, and 200 Hz. The 
maximum tetanic tension was determined from the plateau of the 
frequency-tension curve.
Transmission electron microscopy. Biceps muscle and the kidney 
were briefly fixed with 4% paraformaldehyde and 2.5% glutaralde-
hyde in 0.1 M cacodylate buffer pH 7.4 in situ at room temperature 
(RT), then dissected, removed, and cut into pieces of 1 mm3 and fixed 
for 48 hours in the same solution at 4°C. Tissue blocks were contrasted 
using 1% OsO4 (Roth; RT, 1 hour) and 1% uranyl acetate (Polyscienc-
es) in 70% ethanol (RT, 1 hour). After dehydration, tissue blocks were 
embedded in epoxy resin (Durcopan), and ultrathin sections of 50 
nm thickness were cut using a Leica EM UC6 ultramicrotome (Leica 
Microsystems). Sections were imaged using a Zeiss 910 Transmission 
Electron Microscope and analyzed using ITEM software.
Autophagic flux quantification. Autophagic flux was monitored in 
fed condition using colchicine (C9754, MilliporeSigma) as previously 
described (26). Briefly mice were treated, by i.p. injection, with vehicle 
or with 0.4 mg/kg colchicine. The treatment was administered twice, 
at 24 hours and at 12 hours before muscle collection.
In vivo protein synthesis measurements. In vivo protein synthe-
sis was measured by using the SUnSET technique (25). Mice were 
anesthetized and then given an i.p. injection of 0.040 μmol/g 
puromycin dissolved in 100 μL of PBS. At exactly 30 minutes after 
injection, muscles were collected and frozen in liquid N2 for West-
ern blot analysis.
Statistics. All statistical analyses were performed using GraphPad 
Prism 8 and IBM SPSS (v25). Results are reported as mean ± SEM or 
median ± IQR. To identify differentially expressed genes, the SAM 
method (81) was applied using SAM function in Multiple Experiment 
Viewer (TiGR MeV, Version 4.9). Comparisons of more than 2 groups 
were calculated using 1-way ANOVA with Tukey’s multiple-compar-
ison tests. Correlation analyses were performed using Spearman’s 
correlation coefficient. Significant differences between 2 groups were 
performed by the 2-tailed Student’s t test for independent variables. 
Differences between groups were considered statistically significant 
for P or q < 0.05.
Study approval. Animal experiments were conducted according to 
the Guide for the Care and Use of Laboratory Animals (NIH; National 
Academies Press, 2011), as well as the German law for the welfare of 
animals. All animal experiments were approved by Regierungsprae-
sidium Freiburg (G-15/143), Freiburg, Germany, and by the Italian 
Ministero della Salute, Ufficio VI (Rome, Italy; authorization number 
1060/2015 PR).
Serum samples from healthy controls and patients with CKD 
were collected in accordance with approved protocols by the local eth-
ics committee of the Chamber of Physicians in Hamburg (Germany, 
PV4780 and PV4806) and conducted in accordance with the ethical 
principles stated by the Declaration of Helsinki. Informed consent was 
obtained from all patients.
= 2000). To reduce the batch effects, we applied the integration 
method implemented in the latest Seurat v3 (function FindIntegra-
tionAnchors and IntegrateData, dims = 1:30). The integrated matrix 
was then scaled by ScaleData (default parameters). Principal com-
ponent (PC) analysis was performed on the scaled data (function 
RunPCA, npcs = 30) in order to reduce dimensionality. The number 
of PCs used for each clustering round was data set dependent, and 
they were estimated by the elbow of a principal component analysis 
scree plot. The selected PCs were then used to compute the K-near-
est neighbors graph based on the Euclidean distance (function 
FindNeighbors), which was later used to generate cell clusters using 
function FindClusters. The resolution of FindClusters function for 
each data set was determined (0.6) by exploration of top marker 
genes of each cluster. t-SNE was used to visualize clustering results. 
The top differentially expressed genes in each cluster were found 
using the FindAllMarkers function (min.pct = 0.25, logfc.threshold 
= 0.25) that ran Wilcoxon’s rank-sum tests. The top expressed genes 
were then used to determine the cell type of each cluster. Data avail-
ability: Gene Expression Omnibus GSE172252.
Morphological analysis of kidney and muscle sections. Mouse 
kidneys were perfusion fixed in 4% phosphate-buffered paraformal-
dehyde, embedded in paraffin, and further processed for period acid–
Schiff and H&E stainings. Slices were analyzed using an inverted fluo-
rescence microscope (Zeiss).
RNAscope in situ hybridization. FISH was performed in formalin- 
fixed, paraffin-embedded murine kidney samples using RNA-
scope technology as previously described (85). The RNAscope Mm- 
Inhba-probe from Advanced Cell Diagnostics (catalog 455871) was 
used as the target probe to detect Inhba mRNA. Fluorescent labeling of 
the target probe was performed using OPAL 690 dye from Akoya Bio-
sciences (catalog FP1497001KT, dilution 1:1000). Nuclear costaining 
was performed using the DAPI solution from Advanced Cell Diag-
nostics. Fluorescence imaging was performed using the THUNDER 
Imager (Leica Microsystems).
SDH staining of muscle sections. Muscle cryosections were incubated 
for 3 minutes at room temperature in a sodium phosphate buffer con-
taining 75 mM sodium succinate, 1.1 mM Nitroblue Tetrazolium (Mil-
liporeSigma), and 1.03 mM Phenazine Methosulphate (MilliporeSig-
ma). Samples were then fixed in 10% formal-calcium, dehydrated, 
and cleared in xylene prior to mounting with DPX mounting medium 
(Thermo Fisher Scientific).
Immunofluorescence staining of kidney sections. Cryosections, 4 μm, 
were incubated with antibodies listed in Supplemental Table 1. Hoechst 
costaining allowed us to identify the SS position of myonuclei. Imaging 
was performed with a laser-scanning microscope (Zeiss LSM 800).
Western blot. Muscles were lysed and immunoblotted as previ-
ously described (86). Kidneys were homogenized in lysis buffer (con-
taining 20 mM CHAPS and 1% Triton X-100). After centrifugation 
(15,000g, 15 minutes, 4°C) protein concentration was determined by 
Bio-Rad protein assay. Equal amounts of protein were separated on 
SDS-PAGE. Blots were stripped using Restore Western Blot Stripping 
Buffer (Pierce, Thermo Fisher Scientific) according to the manufac-
turer’s instructions and probed again when necessary. The antibodies 
used are listed in Supplemental Table 1. Uncropped images of blots are 
shown in the supplementaty material.
Muscle tension measurements. Dissection of the hind limb was 
carried out under oxygenated Krebs solution (95% O2 and 5% CO2). 
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